MA47460A - Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase - Google Patents

Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase

Info

Publication number: MA47460A
Authority: MA; Morocco
Prior art keywords: aminotriazolopyridines; kinase inhibitors; kinase; inhibitors; aminotriazolopyridines used
Prior art date: 2017-02-13

Application number

MA047460A

Other languages

English (en)

Inventor

Murugaiah Subbaiah Murugaiah Andappan

Jie Chen

Carolyn Diane Dzierba

Junqing Guo

Amy C Hart

Guanglin Luo

John E Macor

Michael E Mertzman

William J Pitts

Jianliang Shi

Sing-Yuen Sit

Steven H Spergel

Scott Hunter Watterson

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-13

Filing date

2018-02-12

Publication date

2019-12-18

2018-02-12 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2019-12-18 Publication of MA47460A publication Critical patent/MA47460A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA047460A 2017-02-13 2018-02-12 Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase MA47460A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762458144P	2017-02-13	2017-02-13

Publications (1)

Publication Number	Publication Date
MA47460A true MA47460A (fr)	2019-12-18

Family

ID=61283335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047460A MA47460A (fr)	2017-02-13	2018-02-12	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase

Country Status (25)

Country	Link
US (3)	US10913738B2 (fr)
EP (1)	EP3580220B1 (fr)
JP (1)	JP7097373B2 (fr)
KR (1)	KR102549952B1 (fr)
CN (1)	CN110520423B (fr)
AU (1)	AU2018217488B2 (fr)
BR (1)	BR112019016635A2 (fr)
CA (1)	CA3053484A1 (fr)
CY (1)	CY1124978T1 (fr)
DK (1)	DK3580220T3 (fr)
EA (1)	EA039808B1 (fr)
ES (1)	ES2902676T3 (fr)
HR (1)	HRP20212000T1 (fr)
HU (1)	HUE057801T2 (fr)
IL (1)	IL268614B (fr)
LT (1)	LT3580220T (fr)
MA (1)	MA47460A (fr)
MX (1)	MX378515B (fr)
PL (1)	PL3580220T3 (fr)
PT (1)	PT3580220T (fr)
RS (1)	RS62801B1 (fr)
SG (1)	SG11201907335UA (fr)
SI (1)	SI3580220T1 (fr)
SM (1)	SMT202200001T1 (fr)
WO (1)	WO2018148626A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2902676T3 (es) *	2017-02-13	2022-03-29	Bristol Myers Squibb Co	Aminotriazolopiridinas como inhibidores de cinasa
ES2905948T3 (es) *	2017-10-30	2022-04-12	Bristol Myers Squibb Co	Aminoimidazopiridazinas como inhibidores de cinasa
BR112020014516A2 (pt)	2018-01-26	2020-12-08	Bristol-Myers Squibb Company	Aminopirrolotriazinas como inibidores de quinase
CA3105748A1 (fr)	2018-07-09	2020-01-16	Lieber Institute, Inc.	Composes pyridazineg pour inhiber nav1.8
CA3105657A1 (fr)	2018-07-09	2020-01-16	Lieber Institute, Inc.	Composes de pyridine carboxamide pour inhiber nav1.8
AU2019339355A1 (en)	2018-09-13	2021-05-13	Bristol-Myers Squibb Company	Indazole carboxamides as kinase inhibitors
US12172975B2 (en)	2018-09-13	2024-12-24	Bristol-Myers Squibb Company	1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
TWI724753B (zh) *	2019-01-25	2021-04-11	大陸商北京賽特明強醫藥科技有限公司	醯胺基橋連雜環類化合物、及其組合物與應用
AU2020246313B2 (en) *	2019-03-22	2022-08-04	Genfleet Therapeutics (Shanghai) Inc.	Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
IL291828A (en)	2019-10-03	2022-06-01	Bristol Myers Squibb Co	Inazole Carboximides as Kinase Inhibitors
CN115135648B (zh) *	2020-02-13	2024-02-09	劲方医药科技(上海)有限公司	二氢萘啶酮类化合物，其制法与医药上的用途
CN114230565B (zh) *	2020-09-09	2023-10-27	成都奥睿药业有限公司	5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322B (zh) *	2020-09-16	2026-01-06	中国科学院上海有机化学研究所	一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) *	2020-10-19	2023-01-11	Bristol Myers Squibb Co	Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) *	2021-08-02	2023-12-01	大陸商勁方醫藥科技(上海)有限公司	Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR20240135076A (ko)	2021-08-10	2024-09-10	애브비 인코포레이티드	니코틴아미드 ripk1 억제제
EP4495119A4 (fr)	2022-03-16	2025-06-25	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Composé hétérocyclique fusionné, son procédé de préparation et son utilisation médicale
CN116574053A (zh) *	2022-06-21	2023-08-11	中国药科大学	Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es)	2023-01-07	2025-04-09	Syngenta Crop Protection Ag	Compuestos de carboxamida novedosos
AR133939A1 (es) *	2023-09-27	2025-11-19	Bristol Myers Squibb Co	Compuestos de triazolopiridinilo como inhibidores de cinasa
WO2025109114A1 (fr)	2023-11-24	2025-05-30	Syngenta Crop Protection Ag	Nouveaux composés de carboxamide
WO2025149629A1 (fr)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Nouveaux composés de carboxamide
WO2025149637A1 (fr)	2024-01-12	2025-07-17	Syngenta Crop Protection Ag	Nouveaux composés de carboxamide
WO2026008750A1 (fr)	2024-07-05	2026-01-08	Syngenta Crop Protection Ag	Nouveaux composés carboxamides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050288502A1 (en)	2004-06-25	2005-12-29	Andersen Denise L	Substituted heterocyclic compounds and methods of use
CN101437519A (zh) *	2006-03-31	2009-05-20	艾博特公司	吲唑化合物
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
SG186040A1 (en)	2007-11-27	2012-12-28	Cellzome Ltd	Amino triazoles as pi3k inhibitors
WO2010007100A1 (fr) *	2008-07-15	2010-01-21	Cellzome Ltd	Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k
WO2010057877A1 (fr)	2008-11-18	2010-05-27	Cellzome Limited	Triazolo[1,5-a]pyridines 7-pyridinyle- ou phényl-substituées comme inhibiteurs de pi3k
CA2750517A1 (fr)	2009-02-04	2010-08-12	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de 11 beta-hydroxysteroide deshydrogenase 1
US9783573B2 (en)	2012-09-18	2017-10-10	Bristol-Myers Squibb Company	IAP antagonists
HK1219737A1 (zh)	2013-06-10	2017-04-13	Bayer Pharma Aktiengesellschaft	用於治疗癌症的新化合物
AU2015304851A1 (en) *	2014-08-21	2017-02-23	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as RIP1 kinase inhibitors as medicaments
CN108349970B (zh)	2015-11-05	2021-03-05	住友化学株式会社	稠合杂环化合物
WO2018017435A1 (fr)	2016-07-22	2018-01-25	Accro Bioscience Inc.	Composés hétéroaryliques utilisés comme inhibiteurs de la nécrose, composition et application associées
EP3575298B1 (fr)	2017-01-24	2022-03-02	Sumitomo Chemical Company, Limited	Composé hétérocyclique fusionné et composition le contenant
ES2902676T3 (es) *	2017-02-13	2022-03-29	Bristol Myers Squibb Co	Aminotriazolopiridinas como inhibidores de cinasa
ES2905948T3 (es)	2017-10-30	2022-04-12	Bristol Myers Squibb Co	Aminoimidazopiridazinas como inhibidores de cinasa
BR112020014516A2 (pt)	2018-01-26	2020-12-08	Bristol-Myers Squibb Company	Aminopirrolotriazinas como inibidores de quinase
AR123793A1 (es) *	2020-10-19	2023-01-11	Bristol Myers Squibb Co	Compuestos de triazolopiridinilo como inhibidores de quinasas

2018
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt not_active Application Discontinuation
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/fr not_active Ceased
- 2018-02-12 CA CA3053484A patent/CA3053484A1/fr active Pending
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 SM SM20220001T patent/SMT202200001T1/it unknown
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 MX MX2019009555A patent/MX378515B/es unknown
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/fr active Active
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active Active
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en not_active Ceased
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
2020
- 2020-12-09 US US17/116,016 patent/US12157733B2/en active Active
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
2024
- 2024-10-28 US US18/928,275 patent/US20250074909A1/en active Pending

Also Published As

Publication number	Publication date
JP2020507582A (ja)	2020-03-12
DK3580220T3 (da)	2022-01-10
CY1124978T1 (el)	2023-01-05
EA201991915A1 (ru)	2019-12-30
KR102549952B1 (ko)	2023-06-29
ES2902676T3 (es)	2022-03-29
SG11201907335UA (en)	2019-09-27
CN110520423A (zh)	2019-11-29
MX2019009555A (es)	2019-10-02
US10913738B2 (en)	2021-02-09
EA039808B1 (ru)	2022-03-16
RS62801B1 (sr)	2022-02-28
AU2018217488A1 (en)	2019-10-03
HUE057801T2 (hu)	2022-06-28
US20250074909A1 (en)	2025-03-06
AU2018217488B2 (en)	2021-09-23
CN110520423B (zh)	2022-08-23
HRP20212000T1 (hr)	2022-04-01
LT3580220T (lt)	2021-12-27
MX378515B (es)	2025-03-11
CA3053484A1 (fr)	2018-08-16
US20220315580A1 (en)	2022-10-06
IL268614A (en)	2019-10-31
SI3580220T1 (sl)	2022-01-31
WO2018148626A1 (fr)	2018-08-16
SMT202200001T1 (it)	2022-03-21
US12157733B2 (en)	2024-12-03
EP3580220B1 (fr)	2021-11-17
US20190389859A1 (en)	2019-12-26
JP7097373B2 (ja)	2022-07-07
BR112019016635A2 (pt)	2020-04-07
IL268614B (en)	2021-12-01
EP3580220A1 (fr)	2019-12-18
KR20190117006A (ko)	2019-10-15
PL3580220T3 (pl)	2022-02-07
PT3580220T (pt)	2022-01-03

Publication	Publication Date	Title
MA47460A (fr)	2019-12-18	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA48994A (fr)	2020-02-05	Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr)	2019-04-17	Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA40943A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA52486A (fr)	2021-03-10	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
FR25C1047I1 (fr)	2026-01-02	Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA47125A (fr)	2021-04-28	Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3656769A4 (fr)	2021-04-14	Composé aryl-phosphore-oxygène utilisé en tant qu'inhibiteur de kinase egfr
DK3497103T3 (da)	2021-06-14	Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3386981A4 (fr)	2019-06-19	Hétérocycles utiles en tant qu'agents anticancereux
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA46981A (fr)	2019-10-09	Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA51878A (fr)	2020-12-30	Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA53150A (fr)	2021-05-26	Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41140A (fr)	2017-10-17	Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA52063A (fr)	2021-05-26	Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA46745A (fr)	2021-03-31	Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA47736A (fr)	2021-04-21	Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA53110A (fr)	2021-05-12	Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA48803A (fr)	2020-04-08	Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA46878A (fr)	2019-10-02	Composés de benzodiazolium en tant qu'inhibiteurs d'enac